Syntara (SNT) Q1 2027 TU earnings summary

Executive summary

• Phase 2 SNT-4728 results showed reduced putamen inflammation and statistically significant improvement in clinician-assessed motor signs 12 weeks after treatment ended.

• AZALOX advanced to its final Phase 1b dose cohort; a $4.7 million R&D tax incentive supported development programs, and quarter-end cash was $14.1 million.

Financial highlights

• Cash and cash equivalents were $14.060 million at 30 September 2026, versus $13.562 million at 30 June 2026; net operating cash inflow was $649,000.

• Operating cash outflows included $1.989 million for R&D, $1.787 million for staff and $597,000 for administration and corporate costs; R&D and staff represented 89% of net operating cash outflows.

Outlook and guidance

• AZALOX is expected to progress to a Phase 2 component evaluating the selected amsulostat dose in ~30 patients, subject to completion and review of final-cohort safety data.

• SNT-9465 top-line results are expected in Q1 2027; preliminary MESSAGE study results are anticipated in H1 2027.

• Further SNT-4728 analyses of digital endpoints and clinical, biological and imaging biomarkers remain outstanding; additional studies are needed to establish clinical benefit and any effect on disease progression.